Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Innovative Transaction & Process UCITS ETF 10.02.2026 LEGR LN IE00BF5DXP42 1,025,002.00 USD 52,020,268.78 50.751  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 10.02.2026 QCLN.LN IE00BDBRT036 625,002.00 USD 12,141,306.99 19.426  ...

NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: GAAP NET INCOME OF $7 MILLION, OR $0.08 PER DILUTED COMMON SHARE FOR THE QUARTER ENDED DECEMBER 31, 2025. EARNINGS AVAILABLE FOR DISTRIBUTION(1) OF $45 MILLION, OR $0.53 PER ADJUSTED DILUTED COMMON SHARE. GAAP BOOK VALUE OF $19.70 PER COMMON SHARE AT DECEMBER 31, 2025, AND ECONOMIC RETUR...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--  Ferguson Enterprises Inc. (NYSE: FERG; LSE: FERG) announces today that it will issue its results for the period ended December 31, 2025 and provide an update on market opportunities and strategy on Tuesday, February 24, 2026. The results will be available on Ferguson’s website at corporate.ferguson.com at 6:45 a.m. ET/11:45 a.m. GMT. A conference call and webcast of the analyst and investor presentation will be broadcast at 8:30 a.m. ET/1:30 p.m. GMT on the...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--Ferguson Enterprises Inc. (NYSE: FERG; LSE: FERG) announces today that it will issue its results for the period ended December 31, 2025 and provide an update on market opportunities and strategy on Tuesday, February 24, 2026. The results will be available on Ferguson’s website at corporate.ferguson.com at 6:45 a.m. ET/11:45 a.m. GMT. A conference call and webcast of the analyst and investor presentation will be broadcast at 8:30 a.m. ET/1:30 p.m. GMT on the s...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] ≥1), as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube or primary perit...

NEW YORK--(BUSINESS WIRE)--OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, announced today that it will release its Fourth Quarter Fiscal 2025 earnings on Wednesday, February 18th before market open. The Company will conduct a conference call the same day at 10:00 am ET to discuss its quarterly results. What: OneSpaWorld Fourth Quarter Fiscal 2025 financia...

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended December 31, 2025. "2025 extended Tenet's track record of strong revenue growth, disciplined operations, improved margins and robust free cash flow generation," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We see continued demand for acute care and ambulatory surgical services in our markets and are confident in our ability to execute on our str...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC...

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Chimera Investment Corporation (“Chimera”) announced the declaration of its first quarter cash dividend of $0.45 per common share, an increase from its fourth quarter 2025 cash dividend of $0.37. The dividend is payable on April 30, 2026 to common stockholders of record on March 31, 2026. The ex-dividend date is March 31, 2026. The Board of Directors of Chimera also announced the declaration of its first quarter cash dividend of $0.50 per sha...